Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 1
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
Oxazaphosphorine cytostatics: from serendipity to rational drug design.
Voelcker G. Voelcker G. Anticancer Drugs. 2019 Jun;30(5):435-440. doi: 10.1097/CAD.0000000000000782. Anticancer Drugs. 2019. PMID: 30855309 Review.
Influence of the alkylating function of aldo-Ifosfamide on the anti-tumor activity.
Voelcker G. Voelcker G. Anticancer Drugs. 2018 Jan;29(1):75-79. doi: 10.1097/CAD.0000000000000569. Anticancer Drugs. 2018. PMID: 29219879
Immunostimulating and cancer-reductive experimental therapy with the oxazaphosphorine cytostatic SUM-IAP.
Voelcker G. Voelcker G. Anticancer Drugs. 2018 Jun;29(5):411-415. doi: 10.1097/CAD.0000000000000608. Anticancer Drugs. 2018. PMID: 29465464
Causes and possibilities to circumvent cyclophosphamide toxicity.
Voelcker G. Voelcker G. Anticancer Drugs. 2020 Jul;31(6):617-622. doi: 10.1097/CAD.0000000000000912. Anticancer Drugs. 2020. PMID: 32044797
Aldophosphamide-thiazolidine (NSC-613060) an oxazaphosphorine cytostatic that crosses the blood brain barrier.
Voelcker G. Voelcker G. Anticancer Drugs. 2020 Jul 21. doi: 10.1097/CAD.0000000000000974. Online ahead of print. Anticancer Drugs. 2020. PMID: 32701559
Feedback